Khusru Asadullah

University of Potsdam — Germany

Immunology and Microbiology · Life Sciences

45h-index12.6kcitations138works3.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(41), Dermatology and Skin Diseases(38), T-cell and B-cell Immunology(14), Cytokine Signaling Pathways and Interactions(14), Estrogen and related hormone effects(12)

Publications138 total

94 Pharmacokinetics of Guselkumab in Super-Responders and Long-Term Psoriasis Disease Control: Insights from the Phase 3b GUIDE Trial
Journal of Investigative Dermatology·2025
Determinants of Satisfaction with Medical Care for Hidradenitis Suppurativa: Results from a Multicentre Survey in Germany
Dermatology and Therapy·2025· 1 citedOpen Access
Patient involvement in treatment decisions is associated with increased therapy satisfaction in Hidradenitis suppurativa
Frontiers in Medicine·2025Open Access
62281 GUIDE Phase 3b trial results: early intervention with guselkumab results in higher rates of fingernail psoriasis clearance and maintenance of nail response following treatment withdrawal
Journal of the American Academy of Dermatology·2025
61980 Pharmacokinetics of guselkumab in super-responders and long-term psoriasis disease control: insights from the Phase 3b GUIDE trial
Journal of the American Academy of Dermatology·2025
Low satisfaction with medical care among patients with hidradenitis suppurativa: A multicenter study
Journal of the European Academy of Dermatology and Venereology·2025· 3 citedOpen Access
Handlungsempfehlungen bei oraler Candidose unter Biologikatherapie bei Psoriasis – Ergebnisse eines Expertenmeetings
Die Dermatologie·2024· 1 citedOpen Access
50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms
Journal of the American Academy of Dermatology·2024· 3 citedOpen Access
49730 GUIDE trial (part 3): Following guselkumab withdrawal and a long treatment-free period, disease control is rapidly regained upon re-treatment in psoriasis super-responders
Journal of the American Academy of Dermatology·2024Open Access
51791 Guselkumab improves psoriatic skin and HRQoL outcomes across BMI subgroups, including patients with involvement of hard-to-treat areas: results from the real-world PERSIST study
Journal of the American Academy of Dermatology·2024Open Access
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis
JAMA Dermatology·2024· 30 citedOpen Access
Biologika als „game changer“
Deutsche Dermatologie·2024
Identifying the active pharmaceutical ingredient from a mixture of fumaric acid esters for the treatment of psoriasis: Hints from in vitro investigations
Advances in Precision Medicine·2023Open Access
ESDR083 - Prolonged Q16W treatment interval of guselkumab is non-inferior to Q8W dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis
2022
33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study
Journal of the American Academy of Dermatology·2022· 5 cited
Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas
Dermatology and Therapy·2022· 11 citedOpen Access
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
BMJ Open·2021· 77 citedOpen Access
Immunotherapy in Psoriasis
Immunotherapy·2021· 20 cited
Zytokine der IL‐17‐Familie bei der Psoriasis
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2020· 5 citedOpen Access
Cytokines of the IL‐17 family in psoriasis
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2020· 46 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Hans‐Dieter Volk(21), Wolfram Sterry(17), Robert Sabat(14), Kerstin Wolk(10), Wolf‐Dietrich Döcke(9), Ellen Witte(7), Stefanie Kunz(6), Wolf‐Dietrich Döcke(6), Heike Schäcke(5), Arndt Schottelius(4), Hartmut Rehwinkel(4), Sandra Philipp(4), Katrin Witte(4), Markus Friedrich(4), Ulrich Zügel(4), Markus Friedrich(3), Christian Woiciechowsky(3), Wolf‐Dietrich Doecke(3), Gerald Grütz(3), Elizabeth Wallace(2)